Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 10/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.64 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6474029 | 1.00 | OPRD1 (0.64) | OPRD1OPRM1OPRK1CTSLCTSB | |
| SCHEMBL30100565 | 0.94 | OPRD1 (0.73) | OPRD1OPRM1OPRK1 | |
| SCHEMBL21010207 | 0.92 | OPRD1 (0.64) | OPRD1OPRM1OPRK1CTSLCTSB | |
| SCHEMBL30637561 | 0.92 | OPRD1 (0.70) | OPRD1OPRM1OPRK1 | |
| SCHEMBL29505897 | 0.92 | OPRD1 (0.70) | OPRD1OPRM1OPRK1 | |
| SCHEMBL30865865 | 0.92 | OPRD1 (0.70) | OPRD1OPRM1OPRK1 | |
| SCHEMBL17430646 | 0.92 | OPRD1 (0.70) | OPRD1OPRM1OPRK1 | |
| SCHEMBL30637530 | 0.92 | OPRD1 (0.70) | OPRD1OPRM1OPRK1 | |
| SCHEMBL30637587 | 0.92 | OPRD1 (0.70) | OPRD1OPRM1OPRK1 | |
| SCHEMBL30051754 | 0.91 | OPRD1 (0.59) | OPRD1OPRM1OPRK1CTSSMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1254379-A | Method for producing amidated peptides by using fusion proteins | PPL THERAPEUTICS SCOTLAND LTD (GB) | 2000-05-24 | — | — | CN | claimed |
| EP-0979291-A1 | METHODS OF PRODUCTION OF AN AMIDATED PEPTIDE THROUGH THE USE OF A FUSION PROTEIN | PPL Therapeutics (Scotland) Limited (GB) | 2000-02-16 | — | — | EP | claimed |
| WO-1998050563-A1 | METHODS OF PRODUCTION OF AN AMIDATED PEPTIDE THROUGH THE USE OF A FUSION PROTEIN | PPL THERAPEUTICS (SCOTLAND) LTD. (GB) | 1998-11-12 | — | — | WO | claimed |
| US-20260114475-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | MARS, INCORPORATED (US) | 2026-04-30 | — | — | US | disclosed |
| CN-119968127-A | Animal food compositions with improved palatability and customizable properties and methods of making the same | 玛氏公司 | 2025-05-09 | — | — | CN | disclosed |
| EP-4344552-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY, AND METHODS FOR PREPARING THE SAME | MARS, INCORPORATED (US) | 2024-04-03 | — | — | EP | disclosed |
| EP-2571487-B1 | ZWITTERIONIC REAGENTS | SIEMENS HEALTHCARE DIAGNOSTICS INC (US) | 2023-01-04 | — | — | EP | disclosed |
| US-6887384-B1 | Monolithic microfluidic concentrators and mixers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-05-03 | — | — | US | disclosed |
| EP-0438600-B2 | ENZYMES WHICH PARTICIPATE IN C-TERMINAL AMIDATION, AND PRODUCTION AND USE THEREOF | SHISEIDO CO LTD (JP) | 2002-10-09 | — | — | EP | disclosed |
| US-6156555-A | Method of preparing an enzyme participating in C-terminal amidation | SHISEIDO COMPANY LTD. (JP) | 2000-12-05 | — | — | US | disclosed |
| EP-0666318-B1 | Enzyme participating in c-terminal amidation, and method of preparing same and use thereof | SHISEIDO CO LTD (JP) | 2000-11-29 | — | — | EP | disclosed |
| US-5871995-A | Purified enzymes participating in C-terminal amidation | SHISEIDO COMPANY, LTD. (JP) | 1999-02-16 | — | — | US | disclosed |
| EP-0884389-A1 | Enzyme participating in C-terminal amidation, and method of preparing same and use thereof | SHISEIDO COMPANY LIMITED (JP) | 1998-12-16 | — | — | EP | disclosed |
| WO-1998050563-A1 | METHODS OF PRODUCTION OF AN AMIDATED PEPTIDE THROUGH THE USE OF A FUSION PROTEIN | PPL THERAPEUTICS (SCOTLAND) LTD. (GB) | 1998-11-12 | — | — | WO | disclosed |
| EP-0438600-B1 | ENZYMES WHICH PARTICIPATE IN C-TERMINAL AMIDATION, AND PRODUCTION AND USE THEREOF | SHISEIDO CO LTD (JP) | 1996-02-07 | — | — | EP | disclosed |
| EP-0666318-A1 | Enzyme participating in c-terminal amidation, and method of preparing same and use thereof | SHISEIDO COMPANY LIMITED (JP) | 1995-08-09 | — | — | EP | disclosed |
| US-5354675-A | Amidation of glycine | SHISEIDO COMPANY LTD. (JP) | 1994-10-11 | — | — | US | disclosed |
| EP-0447547-B1 | C-TERMINUS AMIDATION ENZYME COMPOSITION, PROCESS FOR ITS PREPARATION AND ITS USE | SHISEIDO CO LTD (JP) | 1994-07-27 | — | — | EP | disclosed |
| EP-0447547-A1 | C-TERMINUS AMIDATION ENZYME COMPOSITION, PROCESS FOR ITS PREPARATION AND ITS USE | SHISEIDO COMPANY LIMITED (JP) | 1991-09-25 | — | — | EP | disclosed |
| EP-0438600-A1 | ENZYMES WHICH PARTICIPATE IN C-TERMINAL AMIDATION, AND PRODUCTION AND USE THEREOF | SHISEIDO COMPANY LIMITED (JP) | 1991-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260114475-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | PIGS, TAS2R13, CEL | OPRD1 3479/4885OPRM1 2292/4885OPRK1 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.